Integer Holdings Faces Class Action Lawsuits After Stock Plummets Over 30%
Plano, Saturday, 13 December 2025.
Shareholders are suing after Integer’s stock crashed over 32% in a single day, following revelations that the company allegedly concealed declining sales of key medical devices.
Legal Actions Mount Following Market Correction
Multiple investor rights law firms, including Bragar Eagel & Squire, P.C., Rosen Law Firm, and Bleichmar Fonti & Auld LLP, have initiated class action lawsuits against Integer Holdings Corporation (NYSE: ITGR) [1][2][3]. The legal proceedings focus on allegations that the medical device manufacturer violated federal securities laws during the class period, which extends from July 25, 2024, to October 22, 2025 [1][2][4]. The lawsuits collectively seek to recover damages for individual and institutional investors who suffered financial losses due to the company’s alleged misrepresentations regarding its market position and product demand [1][4].
Market Reaction to Revised Financial Guidance
The catalyst for the litigation was a sharp decline in Integer’s stock value on October 23, 2025, following a disclosure that altered the company’s financial outlook [3]. On that day, the share price fell from a close of $109.11 on October 22, 2025, to $73.89, representing a single-day decline of -32.279 percent [3]. This sell-off wiped out approximately $35.22 per share in value after the company lowered its sales guidance for 2025 and provided a bleak outlook for the subsequent year [3].
Allegations of Misleading Growth Metrics
Central to the complaints is the accusation that Integer executives overstated the company’s competitive standing within the electrophysiology (EP) manufacturing market [1][2]. The lawsuits allege that the company misrepresented its EP devices as long-term growth drivers for its Cardio and Vascular segment, creating a false impression of stability and expansion [2]. Despite assurances of strong visibility into customer demand, the company was allegedly experiencing a sustained deterioration in sales for two specific EP devices—facts that were not disclosed to investors until the stock collapse [2][3].
Revised Outlook and Investor Timelines
When the correction occurred, Integer adjusted its 2025 sales guidance downward to a range of $1.840 billion to $1.854 billion, a decrease from the previously projected range of $1.850 billion to $1.876 billion [3]. Additionally, the company revealed that the “slower than forecasted” adoption of its EP devices would likely continue, projecting 2026 sales growth to be flat to negative, specifically between -2% and 2% [3]. Investors who acquired Integer securities during the class period have until February 9, 2026, to file motions to be appointed as lead plaintiff in the pending litigation [1][2][4][5].